Back to Directory Laurie Reynolds Email laurie.reynolds@bms.com Institution Bristol-Myers Squibb Company Title Associate Director Request an Update Affiliated Studies P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded P1021: FTC + EFV + ddI Didanosine QD in Naive Children DAIDS Number 10038 Research Area Other Study Status Concluded
P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded
P1021: FTC + EFV + ddI Didanosine QD in Naive Children DAIDS Number 10038 Research Area Other Study Status Concluded
